Vertex Ventures HC | LinkedIn (original) (raw)
Venture Capital and Private Equity Principals
San Francisco, California 2,912 followers
Vertex Ventures HC invests globally in various sectors of the healthcare industry
About us
Vertex Ventures HC is part of a global venture fund network under Vertex Holdings. Vertex Ventures HC invests globally in various sectors of the healthcare industry, including biopharmaceuticals, medical devices and digital health, with ~$400 million of assets under management.
Industry
Venture Capital and Private Equity Principals
Company size
2-10 employees
Headquarters
San Francisco, California
Type
Partnership
Founded
2014
Locations
Employees at Vertex Ventures HC
Updates
-
2,912 followers
2w Edited
๐๐๐ฒ ๐๐๐ฅ๐ฅ๐จ ๐ญ๐จ ๐จ๐ฎ๐ซ ๐ง๐๐ฐ ๐๐๐ง๐ญ๐ฎ๐ซ๐ ๐ ๐๐ฅ๐ฅ๐จ๐ฐ ๐๐ซ๐ข๐ฌ๐ญ๐๐ง ๐. ๐'๐๐๐ข๐ฅ๐ฅ, ๐๐ก.๐.! ๐ We're thrilled to introduce Kristen O'Neill, Ph.D., our new Venture Fellow at Vertex Ventures HC, who joined us after completing her PhD at Brown University in Molecular Pharmacology and Physiology, with a focus on RNA therapeutics in #oncology. Previously she worked at Hyku Biosciences, OpenAI and RebootRx. In recognition of Hispanic Heritage Month, Kristen's journey also exemplifies the invaluable contributions of Latinas in the #healthcare space and the influence of strong role models. ๐ ๐๐๐ซ๐ข๐ญ๐๐ ๐ ๐จ๐ ๐๐๐ซ๐ฌ๐๐ฏ๐๐ซ๐๐ง๐๐ ๐๐ง๐ ๐๐ง๐ง๐จ๐ฏ๐๐ญ๐ข๐จ๐ง Kristen's story is rooted in her Mexican-American background. Inspired by her mother, a Mexican immigrant with an elementary school education, Kristen has embraced the challenges of navigating an industry where Latine women are underrepresented. Her unique perspective as a Mexican-American woman in #biotech enriches our approach to #venturecapital. ๐ ๐ซ๐จ๐ฆ ๐๐ฎ๐ฅ๐ญ๐ฎ๐ซ๐๐ฅ ๐๐ซ๐๐๐ข๐ญ๐ข๐จ๐ง๐ฌ ๐ญ๐จ ๐๐๐ข๐๐ง๐ญ๐ข๐๐ข๐ ๐๐ซ๐๐๐ค๐ญ๐ก๐ซ๐จ๐ฎ๐ ๐ก๐ฌ Kristen's path in science was ignited by a fascinating intersection of culture and research. Under the mentorship of Dr. Louiza Nogaj at Brown University, she investigated the anticancer properties of soursop โ a fruit used in her family's cultural traditions. This experience sparked her passion for scientific inquiry and paved the way for her PhD and eventual transition to life science venture capital. ๐๐จ๐ฆ๐ฆ๐ฎ๐ง๐ข๐ญ๐ฒ ๐๐ง๐ ๐๐ ๐๐ฆ๐๐ง๐ญ Kristen is committed to paying it forward. In her final year of graduate school, she volunteered to teach science to middle school students from low-income neighbourhoods โ many of whom are first-generation Americans or immigrants. By sharing a similar background, she hopes to inspire these students and show them that a career in science is within reach, regardless of their origins. ๐๐ซ๐ข๐ฏ๐ข๐ง๐ ๐๐ก๐๐ง๐ ๐ ๐ข๐ง ๐๐๐ง๐ญ๐ฎ๐ซ๐ ๐๐๐ฉ๐ข๐ญ๐๐ฅ Kristen plans to support others entering the field by mentoring through programs like VC University, where she was previously a scholarship recipient. Her goal is to drive positive change and increase #diversity in the industry. ๐๐๐ฒ๐จ๐ง๐ ๐ญ๐ก๐ ๐๐๐ Outside of her professional pursuits, Kristen loves to cook traditional Mexican cuisine and is passionate about making science accessible to underrepresented communities. Her multifaceted approach to life and career embodies the spirit of innovation and cultural pride. Join us in celebrating Hispanic Heritage Month by learning more about Kristenโs inspiring story and how sheโs making a difference below ๐#HispanicHeritageMonth #DiversityInVC #WomenInTech #Biotech #Innovation #LifeSciences #VentureCapital #Innovation #LatinasInBiotech #LatinasinBio #molecularbiology #lifescience #RNA Lori Hu Christine Brennan Sahil Chopra Amanda Chen David Van Meter- +5
- +5
-
2,912 followers
2w Edited
๐ข ๐๐ฑ๐๐ข๐ญ๐ข๐ง๐ ๐ง๐๐ฐ๐ฌ! ๐ MSD and EyeBio have just initiated the Phase 2b/3 BRUNELLO trial evaluating Restoretโข for their innovative treatment of diabetic macular edema. This marks a significant step forward in addressing this debilitating eye condition. Congratulations to Dr. David Guyer and the entire EyeBio team on this achievement! This milestone comes on the heels of Merck's acquisition of EyeBio for up to $3 billion, a testament to the promising potential of their work. As Dr. David Guyer stated, "The initiation of the BRUNELLO trial marks an important milestone as we work with our new colleagues at Merck, driven by the common purpose to deliver new, much needed options for patients with diabetic macular edema." We're eager to see the results of this trial and the impact it could have on the lives of those affected by diabetic macular edema. ๐ Read the full press release here: https://lnkd.in/e2a5V9Ga #DiabeticMacularEdema #ClinicalTrials #Innovation #Healthcare #Biotech #Lifesciences Lori Hu Christine Brennan Sahil Chopra Amanda Chen David Van Meter -
2,912 followers
3w Edited
We are thrilled to welcome Dr. Thomas Daniel to our team! ๐๐ฌ As a physician, scientist and R&D executive, Dr. Daniel brings over two decades of unparalleled experience in the life sciences sector. With a proven track record in fostering #innovation, building high-performing R&D teams, and driving strategic investments, Dr. Danielโs broad clinical expertise will be invaluable in supporting our portfolio companies to bring new medicines to patients and evaluating new investment opportunities. His multifaceted career includes serving as a Venture Partner at ARCH Venture Partners and President of Global Research and Early Development at Celgene. Dr. Daniel has also been a guiding force on numerous boards, including Juno, Sana Biotechnology, Inc. and Vir. He is a founder and chairs the Board of Managers of Life Science Cares San Diego, is a Trustee of Reed College and is a Director at Scripps Research. A nephrologist and former academic investigator, he was previously C.M. Hakim Professor of Medicine and Cell Biology at Vanderbilt University. Tom Daniel joins us alongside VVHC's venture advisors and industry veterans, George Golumbeski and Faheem Hasnain. His focus on patients and the translation of medicines drives his work, as well as his passion for mentoring #entrepreneurs and raising the bar for emerging #biotech companies. We're excited to have Dr. Daniel join us as we continue to drive advancements in the life sciences field. Join us in welcoming Dr. Tom Daniel as our Venture Advisor! ๐๐ Find out more about our team here: https://lnkd.in/g7y_DZqZ Lori Hu Christine Brennan Sahil Chopra Amanda Chen David Van Meter #LifeSciences #Innovation #Leadership #Venturecapital #Biotech #Founders #Entrepreneur -
2,912 followers
1mo Edited
๐๐ฉ๐ฝ๐ค๐ฉ๐ป Today, we commemorate Women's Equality Day, marking the anniversary of the 19th Amendment's ratification, granting American women the right to vote. This year's theme, "Equality Starts with Empowered Women," underscores the importance of fostering women's well-being and resilience in both the workplace and society. At Vertex Ventures HC (VVHC), we are committed to supporting female entrepreneurs, celebrating the achievements of the women's rights movement, and empowering women in all aspects of life. Our Managing Directors, Lori Hu and Christine Brennan, share their insights on how VVHC play a crucial role in bridging the gender gap. 1๏ธโฃ More than 80% of our investments have been made in companies with #female leadership, such as #founders, C-suite, and board members. We strive to increase our investment in women. 2๏ธโฃ We formed a Fellowship Programme to provide MD, PhD and PharmD students and recent graduates exposure to #healthcare venture investing and #entrepreneurship. 3๏ธโฃ We are a member of Breaking 7%, which aims to connect women in healthcare investment, business development and deal-making roles to foster strong connections and ultimately be a driving force to change. 4๏ธโฃ Christine co-founded the Series 2X initiative, where senior-level women in healthcare VCs support deal flow and discuss ways to increase funding for women-led companies. ๐ Read more on our perspectives here: https://lnkd.in/gd76UCdcSahil Chopra Amanda Chen #FemaleFounders #NationalWomensEqualityDay #Equality #Inclusivity #GenderGap #FemaleEntrepreneurs #Funding #VentureCapital #VC -
2,912 followers
1mo Edited
Congratulations Moximed on raising their latest USD 61M Series D round! ๐ This is a testament to the company's innovative and groundbreaking work in addressing knee osteoarthritis. The new funds will accelerate the US commercialization of the MISHAยฎ Knee System - the worldโs first implantable shock absorber (ISA) for knee osteoarthritis. Read more: https://lnkd.in/eYh3WgxQ Lori Hu Christine Brennan Sahil Chopra Amanda Chen #fundraising #kneeosteoarthritis #innovation #medtech #sportsmedicine
10,337 followers
1mo Edited
#NEWS: Weโve secured #SeriesD financing for $91 million: https://lnkd.in/eYh3WgxQFunds will be used to accelerate U.S. commercialization of the MISHAยฎ Knee System. Weโre grateful for the support from lead investor Elevage Medical Technologies, new investors Cormorant Asset Management, LP, Warren Point Capital, and existing investors New Enterprise Associates (NEA), Future Fund, Advent Life Sciences, Glide Healthcare, Vertex Ventures HC, GBS Venture Partners, and Morgenthaler.#Financing #MedTech #MoveToMISHA #KneeOA #Orthopedics #SportsMedicine - ๐ข We are pleased to announce that Merck (NYSE: MRK) has completed the acquisition of our portfolio company, EyeBio, for up to $3 billion. This outcome is a testament to the dedication and brilliance of the EyeBio team, led by David Guyer (Co-founder, President & Chief Executive Officer) and Tony Adamis (Co-founder, Chief Scientific Officer). EyeBioโs lead candidate, Restoretโข, is scheduled to advance into a pivotal Phase 2b/3 trial to evaluate its potential for the treatment of patients with diabetic macular edema in the second half of 2024. This acquisition is a significant win for patients, the ophthalmology field, and the investment community. Congratulations to everyone involved in this incredible journey!๐ Read more: https://lnkd.in/eRdnnxBZ Christine Brennan Lori Hu Sahil Chopra Amanda Chen #eyecare #opthalmology #biotech #acquisition #lifesciences #biopharma
-
2,912 followers
3mo Edited
๐ฃ Calling all aspiring #healthcare #investors! Are you passionate about bringing groundbreaking innovations to the healthcare industry? Curious about the exciting world of venture capital (#VC) and how it fuels life-changing discoveries? Join us for an exclusive FREE live Zoom webinar where we'll answer your questions about the Vertex Ventures HC #Venture #Fellowship program. In this webinar, you'll learn: โ VC 101: Demystify the world of venture capital, understand how it funds promising healthcare startups and careers in VC โ Vertex Ventures HC Overview: Learn about Vertex Ventures HC, our investment focus areas, and diligence & investment process โ Fellowship Program: What to expect in our Venture Fellowship program and process โ Q&A: Ask us anything! This webinar is perfect if you're an aspiring VC investor interested in a career in VC ๐ Don't miss this chance to: ๐ Learn what VCs are looking for in terms of background and experience ๐ Get advice for building your network, getting your foot in the door, and interviewing for venture capital roles Panelists: - Lori Hu, Managing Director at Vertex Ventures HC - Amanda Chen, Senior Associate at Vertex Ventures HC - Sneha Batheja, Investor at The John Hopkins University and Former Vertex Ventures HC Fellow ๐ Friday June 14, 2024: 2PM EST / 11AM PST ๐ Register today at: https://lnkd.in/dwfwJxNz #VentureCapital #Startup #Investing #CareerOpportunity #Webinar #VentureFellowship #Networking #ProfessionalDevelopment #WomeninVC -
2,912 followers
4mo Edited
We are thrilled to announce a major exit in our portfolio. Only 7 months after VVHC led the Series A extension to invest in EyeBio, the Company has signed an agreement to be acquired by Merck for 1.3billionupfront,withatotalconsiderationofupto1.3 billion upfront, with a total consideration of up to 1.3billionupfront,withatotalconsiderationofupto3 billion. This successful exit validates VVHCโs investment strategy, which is built upon a patient benefit and value creation-driven approach: โก๏ธ A focus on companies with deep management expertise, such as EyeBio co-founders, CEO David Guyer and CSO Tony Adamis, who along with the rest of the team, are developing therapies for patients still not served or underserved by existing therapies. โก๏ธ Along with excellent investment partners exemplified by the EyeBio syndicate: SV Health Investors, Samsara BioCapital, Jeito Capital, MRL Ventures Fund LLC, Omega Funds and Bain Capital Life Sciences. Congratulations to the entire EyeBio team for this amazing outcome. We look forward to monitoring the development of Restoretโข for the treatment of diabetic macular edema and neovascular age-related macular degeneration, as well as the rest of the EyeBio pipeline.https://lnkd.in/erazsGCB Lori Hu Christine Brennan Sahil Chopra Amanda Chen
Merck to Acquire EyeBio | EyeBio https://eyebiotech.com
Join now to see what you are missing
Similar pages
Browse jobs
- Software Intern jobs 1,932 open jobs
- Principal Software Engineer jobs 84,970 open jobs
- Developer jobs 344,797 open jobs
- Associate Portfolio Manager jobs 4,605 open jobs
- Private Equity Analyst jobs 4,854 open jobs
- Technology Officer jobs 436,888 open jobs
- Investment Banking Analyst jobs 24,315 open jobs
- Chief Business Officer jobs 5,472 open jobs
- Associate Consultant jobs 497,370 open jobs
- PHD jobs 122,227 open jobs
- Finance Officer jobs 62,417 open jobs
- Chief Executive Officer jobs 186,821 open jobs
- Innovation Manager jobs 30,382 open jobs
- Process Development Scientist jobs 10,866 open jobs
- Equity Analyst jobs 8,795 open jobs
- Healthcare Specialist jobs 34,468 open jobs
- Chartered Financial Analyst jobs 10,504 open jobs
- Senior Associate jobs 131,985 open jobs
- Associate Director jobs 156,364 open jobs
- Analyst jobs 760,055 open jobs